好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Cortical High-Beta EEG Response to Dopaminergic Therapy in Parkinson’s Disease
Movement Disorders
P4 - Poster Session 4 (5:30 PM-6:30 PM)
3-006

To investigate cortical oscillations in Parkinson’s disease (PD) at the time of foot movements and their response to dopaminergic therapy.

Elevated high-beta EEG power (high-β, 21-35 Hz) in the sensorimotor cortex has been reported in PD. Elevated high-β is hypothesized to be disruptive to movement. Dopaminergic medication reduced cortical high-β in a rodent model of PD. However, it is unclear whether PD medication desynchronizes high-β generally or specifically at the time of movement.

Whole-head EEG was recorded from 15 PD patients [2 women; median age 65 years, range 57-79; median PD duration 8 years, range 1-20; median levodopa equivalent daily dose 650 mg, range 300-1880]. Patients were assessed while ON dopaminergic medication (PD-ON) and OFF medication after 12-hour withdrawal (PD-OFF). We also tested 15 age-matched healthy controls (HC). Rest EEG was measured while participants passively viewed forward movement down a virtual hallway but did not step. For active step trials, participants had to step alternately with foot pedals to move through the virtual hallway. High-β power was assessed at rest and active trials. We then assessed high-β at “high-intensity” toe-down periods of the right foot and at “low-intensity” periods between toe-down periods. The difference in high-β between “high-intensity” and “low-intensity” phases was determined at premotor/frontal, motor, and parietal clusters and compared between PD-ON versus PD-OFF and between PD-ON versus HC.  

PD-ON and PD-OFF had similar levels of cortical high-β power. HC dramatically reduced cortical high-β power from rest to stepping, but this effect was not seen in PD-OFF nor PD-ON. In all cortical clusters, high-β desynchronized from high-to-low intense periods in PD-ON compared to PD-OFF. High-β desynchronization from high-to-low intensity did not differ between PD-ON and HC.  

Dopaminergic medications desynchronized cortical high-beta power specific to the time of movement. High-beta desynchronization may play a role in motor improvements.   

Authors/Disclosures

PRESENTER
No disclosure on file
Karlo J. Lizarraga, MD, MS, FAAN (University of Rochester) Dr. Lizarraga has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for FHC. The institution of Dr. Lizarraga has received research support from BlueRock. The institution of Dr. Lizarraga has received research support from Roche. The institution of Dr. Lizarraga has received research support from NIH/NINDS. Dr. Lizarraga has received personal compensation in the range of $500-$4,999 for serving as a Speaker with International Parkinson and Movement Disorders Society. Dr. Lizarraga has received personal compensation in the range of $0-$499 for serving as a Reviewer with National Institutes of Health. Dr. Lizarraga has a non-compensated relationship as a Editorial Board Member for Brain & Life with 好色先生 that is relevant to AAN interests or activities.
Julianne Baarbé No disclosure on file
No disclosure on file
Robert E. Chen, MD, MBBChir (Toronto Western Hospital) Dr. Chen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Chen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merz. Dr. Chen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ipsen. Dr. Chen has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for International Federation of Clinical Neurophysiology. Dr. Chen has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Movement Disorders. The institution of Dr. Chen has received research support from Canadian Institutes of Health Research. The institution of Dr. Chen has received research support from Natural Science and Engineering Research Council of Canada. Dr. Chen has received research support from Parkinson Foundation. The institution of Dr. Chen has received research support from National Organization for Rare Disease. The institution of Dr. Chen has received research support from Abbvie.